ABSTRACT -To identify candidate biomarker gene sets to evaluate the potential risk of chemicalinduced glutathione depletion in livers, we conducted microarray analysis on rat livers administered with phorone (40, 120 and 400 mg/kg), a prototypical glutathione depletor. Hepatic glutathione content was measured and glutathione depletion-responsive gene probe sets (GSH probe sets) were identified using Affymetrix Rat Genome 230 2.0 GeneChip by the following procedure. First, probe sets, whose signal values were inversely correlated with hepatic glutathione content throughout the experimental period, were statistically identified. Next, probe sets, whose average signal values were greater than 1.5-fold compared to those of controls 3 hr after phorone treatment, were selected. Finally, probe sets without unique Entrez Gene ID were removed, ending up with 161 probe sets in total. The usefulness of the identified GSH probe sets was verified by a toxicogenomics database. It was shown that signal profiles of the GSH probe sets in rats treated with bromobenzene were strongly altered compared with other chemicals. Focusing on bromobenzene, time-course profiles of hepatic glutathione content and gene expression revealed that the change in gene expression profile was marked after the bromobenzene treatment, whereas hepatic glutathione content had recovered after initial acute depletion, suggesting that the gene expression profile did not reflect the hepatic glutathione content itself, but rather reflects a perturbation of glutathione homeostasis. The identified GSH probe sets would be useful for detecting glutathione-depleting risk of chemicals from microarray data.
IDENTIFICATION OF GLUTATHIONE DEPLETION-RESPONSIVE GENES USING PHORONE-TREATED RAT LIVER

INTRODUCTION
Microarray analysis displays tens of thousands of nucleotide probes on a substrate surface, and enables the measurement of mRNA levels of large numbers of genes simultaneously (Rockett and Dix, 2000) . Microarray analysis is aimed at toxicological investigation and is called toxicogenomics (Boverhof and Zacharewski, 2006) . This is thought to be useful for such points as: I) understanding the molecular mechanisms of toxicity, II) the early prediction of drug toxicity risk, and III) improvement in extrapolation of experimental animal data to humans (Orphanides, 2003) . At present, the liver is one of the most favored target organs in Toxicogenomics studies for the following reasons: 1) it is exposed to relatively higher levels of administered drugs, 2) it is a relatively homogenous organ and thus easy to sample, and 3) it can dramatically affect the pharmaco/toxico-kinetics of the drugs in the body by the first-pass effect (Parkinson, 2001) . Furthermore, hepatotoxicity has been a critical concern in drug development (Kaplowitz, 2004; Li, 2002) .
These issues have motivated toxicologists to investigate liver toxicity using the toxicogenomics technique.
The Toxicogenomics Project in Japan (TGP; http://wwwtgp.nibio.go.jp/index-e.html) has been completed by the National Institute of Health Sciences and 17 pharmaceutical companies after 5 years' collaboration from 2002 (Urushidani and Nagao, 2005; Takashima et al., 2006) . In the project, five rats per group were administered with toxicological prototype drugs once daily, where three dose-ranges were set, and liver samples were collected 3, 6, 9 and 24 hr after a single treatment, as well as 4, 9, 15 and 29 days after repetitive treatment. Of the collected liver samples, three samples per group were subjected to microarray analysis using the Affymetrix GeneChip system. In addition, toxicological data, such as blood chemistry and histopathology, were collected simultaneously. Such a large-scale database would be invaluable for scientists not only as a reference database but also as a resource for screening candidate toxicogenomic biomarker sets.
Glutathione serves vital functions in detoxifying electrophiles and scavenging free radicals (Lu, 1999) , and hepatotoxicity caused by glutathione depletion has been intensely investigated. In the case of acetaminophen overdosage, acetaminophen is metabolically activated by phase I drug metabolizing enzymes to form a reactive metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which covalently binds to proteins (Dahlin et al., 1984; James et al., 2003) . Although NAPQI can be detoxified by glutathione conjugation under ordinary conditions, an excess dose of acetaminophen depletes 90% of hepatic glutathione, and reactive NAPQI forms protein adducts (Mitchell et al., 1973; James et al., 2003) , resulting in hepatocyte necrosis.
Previously, sixty-nine gene probe sets of Rat Genome U34A GeneChip (Affymetrix, Inc.) were identified as glutathione depletion-responsive genes, using L-buthionine-(S,R)-sulfoximine (BSO) as a glutathione-depleting agent (Kiyosawa et al., 2004) . Although the probe sets were thought to be useful for evaluation of drug-induced glutathione deficiency in rat liver, the study had two major drawbacks. First, the sample size used for the study was relatively small: one dose setting and one time point of observation, using 4 rats per group. Secondly, BSO depletes hepatic glutathione by inhibiting γ-glutamylcysteine synthetase, a key enzyme of glutathione synthesis (Moinova and Mulcahy, 1999) . In the case of acetaminophen-induced glutathione depletion, an overdose of acetaminophen depletes hepatic glutathione by extended conjugation of glutathione with activated metabolites such as NAPQI. Therefore, BSO-induced glutathione depletion would probably not appropriately reflect the druginduced one. For these reasons, an alternative glutathione-depleting model, other than the BSO model, would be useful for better explaining drug-induced glutathione depletion, in view of the gene expression profile.
Phorone is an α, β-unsaturated compound, which strongly depletes hepatic glutathione content by conjugation with glutathione, by action of glutathione Stransferase (GST), and is excreted from liver (Boyland and Chasseaud, 1967; van Doorn et al., 1978) . Comparing the glutathione-depleting mechanism of phorone with that of BSO, the phorone-induced glutathione depletion mechanism is thought to be more similar to that induced by acetaminophen overdosing, where activated metabolites such as NAPQI deplete glutathione by being conjugated with glutathione and then are excreted from liver.
In this paper, we present candidate biomarker probe sets of RAE 230A GeneChip for evaluation of the potential risk of drug-induced glutathione depletion in rat livers, using phorone as a glutathione-depleting agent. The toxicological significance of identified biomarker probe sets was examined using a large-scale TGP database.
MATERIALS AND METHODS
Chemicals
Phorone, acetaminophen, thioacetamide, phenylbutazone, glibenclamide, methapyrilene hydrochloride and perhexiline maleate were purchased from Sigma-Aldrich (St. Louis, MO, USA). Clofibrate, aspirin and chlorpromazine were purchased from Wako Pure Chemical Industries (Osaka, Japan). Bromobenzene, hexachlorobenzene, carbon tetrachloride and coumarin were purchased from Tokyo Chemical Industry (Tokyo, Japan).
Animal treatment
Six-week old-male Crj:CD(SD)IGS rats (Charles River Japan, Kanagawa, Japan) were used in the study. The animals were individually housed in stainless-steel cages in a room that was lighted for 12 hr (7:00-19:00) daily, ventilated with an air-exchange rate of 15 times per hour, and maintained at 21-25°C with a relative humidity of 40-70%. Each animal was allowed free access to water and pellet food (CRF-1, sterilized by Vol. 32 No. 5 radiation, Oriental Yeast Co., Japan). Five rats per group were administered with phorone (40, 120 or 400 mg/kg, i.p.). Five rats per group were administered orally with acetaminophen (1000 mg/kg), bromobenzene (300 mg/kg), clofibrate (300 mg/kg), chlorpromazine (45 mg/kg), glibenclamide (1000 mg/kg), methapyrilene (100 mg/kg), phenylbutazone (200 mg/kg), aspirin (450 mg/kg), carbon tetrachloride (300 mg/kg), coumarin (150 mg/kg), hexachlorobenzene (300 mg/ kg), perhexiline maleate (150 mg/kg) or thioacetamide (45 mg/kg). Blood samples were collected in tubes containing heparin lithium 3, 6, 9, or 24 hr after treatment for biochemical assay. The animals were then euthanized and the liver was removed and soaked in RNAlater (Ambion, Austin, TX, USA) immediately after sampling and stored at −80°C until use for gene expression analysis. In the animals treated with phorone or bromobenzene, another aliquot of liver sample was immediately frozen in liquid nitrogen for measurement of hepatic glutathione contents. The remaining liver samples were then removed and fixed in 10% neutral buffered formalin for histopathological examination. The experimental protocol was reviewed and approved by the Ethics Review Committee for Animal Experimentation of the National Institute of Health Sciences.
Plasma biochemistry
Activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in plasma were determined using a 7080 Clinical Analyzer (Hitachi High-Technologies Corporation, Tokyo, Japan).
Histopathology
The fixed samples were dehydrated through graded alcohols and embedded in paraffin. Serial sections 2-3 μm thick were stained with hematoxylin and eosin for pathological examination.
Measurement of hepatic glutathione content
The liver samples (0.1 g) were homogenized with 5% 5-sulfosalicylic acid (Sigma-Aldrich) and centrifuged at 12,000 rpm for 10 min at 4°C. The supernatant was used for the measurement of total glutathione content in the liver using the Total Glutathione Quantification Kit (Dojindo Laboratories), according to the manufacturer's instructions.
Microarray analysis
Liver samples were homogenized with RLT buffer, supplied in the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), using Mill Mixer (Qiagen) and zirconium beads. Total RNA was isolated using Bio Robot 3000 (Qiagen). DNase I treatment was performed using RNase-Free DNase set (Qiagen) for 15 min at room temperature. GeneChip analysis was performed on 3 out of 5 samples in each group according to the Affymetrix standard protocol. Briefly, a total of RNA of 5 μg prepared from the individual rat liver samples was used for cDNA synthesis using the T7-(dT) 24 primer (Affymetrix) and Superscript Choice System (Invitrogen, Carlsbad, CA, USA). The cDNA was purified using cDNA Cleanup Module (Affymetrix), and biotin-labeled cRNA mix was transcribed using the BioArray High Yield RNA Transcription Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA). Ten micrograms of fragmented cRNA cocktails were hybridized to the RAE 230A GeneChip array for all samples except for that of phorone-and corresponding vehicle-treated rats, which were hybridized to the RAE 230 2.0 array for 18 hr at 45°C at 60 rpm. GeneChip was washed and stained using Fluidics Station 400 (Affymetrix) according to the Affymetrix standard protocol and scanned using Gene Array Scanner (Affymetrix). The scanned data images were digitalized using Affymetrix Microarray Suite ver. 5.0 (Affymetrix), and the data was scaled by adjusting the mean Signal value to 500.
Microarray data analysis
We primarily use gloval mean normalization for data analysis in our project. Firstly, using vehicle-and phorone (40 and 120 mg/kg)-treated rats, where the total number of rats was 36, both Spearman's and Pearson's correlation coefficients between the signal value and hepatic glutathione content were calculated for all the probe sets that existed on the RAE 230A array. The probe sets with both Spearman's coefficients and Pearson's coefficients less than -0.329 were chosen as statistically significant inverse correlations (N=36, p < 0.05). Secondly, probe sets, whose average signal values in 120 mg/kg phorone-treated rats at 3 h were above 1.5 compared to those of corresponding controls were selected. Then, probe sets, whose detection calls determined by Microarray Suite ver. 5.0 were all present 3 hr after phorone treatment, were selected. Finally, annotation for each probe set was obtained using NetAffx Website (Liu et al., 2003) , and probe sets without unique Entrez Gene ID were excluded from the analysis. For each probe set, the signal data was z-score normalized in the vehicle-and phorone (40, 120 and 400 mg/kg)-treated group. All the z-score normalized signal data were presented as a heat map and z-score normalized glutathione content data was also presented as a heat map.
Statistical analysis
Dunnett's test was performed for serum chemistry and glutathione content data (between phoronetreated rat groups and vehicle-treated group at the same time point), using R software (www.r-project.org). Serum chemistry data (other than that of phoronetreated rats) was analyzed by F-test to evaluate the homogeneity of variance. If the variance was homogeneous, Student's t-test was applied. If the variance was heterogeneous, Aspin-Welch's t-test was performed (Snedecor and Cochran, 1989 
RESULTS
Plasma biochemistry in phorone-treated rats
There were no apparent fluctuations of plasma ALT activity in 40 and 120 mg/kg phorone-treated rats throughout the experimental period (Fig. 1) . Plasma ALT activity was obviously elevated in rats 24 hr after 400 mg/kg phorone treatment.
Glutathione content in phorone-treated rat liver
Hepatic glutathione content was significantly decreased 3, 6 and 9 hr for 40 mg/kg phorone-treated rats, and recovered above the control level 24 hr after treatment (Fig. 2 ). Hepatic glutathione content was significantly decreased to an 8.3-fold lower level compared with the control 3 hr after the 120 mg/kg phorone-treated rats, and gradually recovered 6 and 9 hr after treatment, resulting in a 1.52-fold higher level compared with control 24 hr after treatment. Hepatic glutathione content was significantly decreased to a 22-to 30-fold lower level compared with control 3, 6 and 9 hr after the 400 mg/kg phorone-treated rats, and recovered to the control level 24 hr after treatment. Identification of glutathione deficiency-correlated gene probe sets A hundred and sixty-one probe sets were identified as glutathione deficiency-correlated gene probe sets, or GSH probe sets (Table 1) , and classified to 5 groups, i.e., "antioxidant, phase II drug metabolizing enzymes, and oxidative stress markers" (11 probe sets), "transporter" (13 probe sets), "metabolism" (20 probe sets), "transcription factors and signal transduction-related, and protein turnover-related genes" (79 probe sets), and "miscellaneous" (37 probe sets). Both the z-score transformed hepatic glutathione content and z-score transformed signal levels of the GSH probe sets are presented as a heat map (Fig. 3) . PCR primers and TaqMan probes for 4 genes from the list above, namely tribbles homolog 3 (accession no. AB020967), heme oxygenase-1 (NM_012580), thioredoxin reductase-1 (NM_031614) and γ-glutamylcysteine synthetase modifier subunit (NM_017305), were synthesized and quantitative RT-PCR was performed using the TaqMan Universal PCR Master Mix (Applied Biosystems), and the mRNA level was quantified with a GeneAmp 5700 Sequence Detection System (Applied Biosystems) according to the manufacturer's instructions. It was confirmed that quantification by GeneChip was sufficient (data not shown).
Plasma biochemistry and histopathological findings in rat liver treated with various hepatotoxicants
Rats treated with bromobenzene, methapyrilene or thioacetamide showed significant increase in plasma ALT activity 24 hr after treatment (Table 2 ). Rats treated with acetaminophen, chlorpromazine, glibenclamide or methapyrilene showed significant increase in serum AST activity 24 hr after treatment. Rats treated with acetaminophen, bromobenzene, methapyrilene, carbon tetrachloride, coumarin or thioacetamide showed histopathological changes 24 hr after treatment, while rats treated with clofibrate, chlorpromazine, glibenclamide, phenylbutazone, aspirin, Three rats per group were treated with 40, 120 or 400 mg/kg phorone or vehicle, and the livers were removed 3, 6, 9 and 24 hr after treatment. Hepatic glutathione content (total) was measured and the data are presented as mean ± S.D. ** and *, p<0.01 and p<0.05 by Dunnett's test, respectively. Glutathione content and GeneChip signal data for GSH probe sets, obtained from rat livers treated with phorone or vehicle, are transformed to z-score by row, and are presented as a heat map where low and high scores are colored in white and black, respectively. Each row represents a probe set, and the vertical order of the probe sets is the same as that presented in Table 1 . Each column represents individual rats treated either with phorone or vehicle. Table 2 . Plasma biochemistry and histopathological findings in rat liver treated with various prototypical hepatotoxicants. Rat groups consisting of 5 animals were administered with the compounds listed in the table and euthanized 24 hr after treatment. Both blood chemistry and histopathology data are summarized using the 5 rats. Note that microarray analysis was conducted using 3 rats out of the 5. The data are presented as mean ±S.D. * and **, p<0.05 and p<0.01, respectively, determined by two-sample t-test.
hexachlorobenzene or perhexiline maleate did not show any histopathological changes.
Gene expression analysis for rat liver treated with various hepatotoxicants PCA was performed using GSH probe sets for GeneChip data obtained from rat livers 24 hr after treatment with various prototypical hepatotoxicants (Fig. 4) . It was obvious from the figure that a few compounds were distributed to the direction of the first principal component (PC 1) with relatively high contribution (57.6%), i.e., 300 mg/kg bromobenzene, 150 mg/kg coumarin, 1000 mg/kg acetaminophen, and 45 mg/kg thioacetamide, in that order. Rats treated with other chemicals or corresponding vehicles showed no apparent shift toward the PC 1 axis, but showed dispersed distributions along the PC 2 axis.
Glutathione content in rat livers treated with bromobenzene
From PCA using GSH probe sets, we found that bromobenzene was the most potent GSH-depletor among the compounds tested. In order to confirm this, hepatic glutathione content in the liver treated with this compound was actually quantified. It was found that the contents were significantly reduced 3, 6 and 9 hr after 300 mg/kg bromobenzene treatment (Fig. 5) . It appeared that some of the treated rats showed recovery or rather rebound of GSH contents 24 hr after treatment since the mean value recovered to the control level with large variance.
Time-course of gene expression profile in rat liver treated with bromobenzene
In order to analyze the time dependent correlation between GSH contents and gene expression changes, PCA was performed by adding the data of 3, 6, and 9 hr after bromobenzene treatment to the same PCA was performed using GSH probe sets for GeneChip data of rat livers 24 hr after treatment with various hepatotoxicants. Each spot, colored by chemical type, represents individual samples. Bromobenzene, coumarin, and acetaminophen showed apparent shift from control, suggesting a perturbation of glutathione homeostasis in the liver after treatment. data in Fig. 4 . Fig. 6 shows that signal profiles of GSH probe sets did not apparently differ from those of controls, 3 and 6 hr after 300 mg/kg bromobenzene treatment. After 9 hr, they shifted away toward both PC1 and PC2 axis, approaching the position of 24 hr on PC1 axis.
DISCUSSION
Hepatic total glutathione content was significantly decreased in all the phorone-treated groups 3 hr after treatment (Fig. 2) . After acute glutathione depletion, the hepatic glutathione content gradually recovered from 6 hr in the phorone-treated group (40 and 120 mg/kg), resulting in a significantly higher glutathione content, compared to the vehicle-treated rats 24 hr after treatment. Plasma ALT activity was elevated from 9 hr after 400 mg/kg phorone treatment, suggesting slight hepatocellular injury. Since secondary undesirable effects caused by slight hepatotoxicity (other than glutathione depletion) might affect the gene expression profile, we excluded GeneChip data of the 400 mg/kg phorone-treated rats from analysis for identification of the glutathione depletion-responsive gene probe sets. Previously, candidate marker genes whose mRNA levels were inversely correlated with hepatic glutathione content were identified using L-buthionine-[S,R]-sulfoximine (BSO) as a glutathione-depleting agent (Kiyosawa et al., 2004) . In the present study, we used phorone as a glutathione-depleting agent instead of BSO. We identified a total of 161 probe sets, referred to as 'GSH probe sets', whose signal showed Three rats per group were treated with 300 mg/ kg bromobenzene or vehicle, and the livers were removed 3, 6, 9 and 24 hr after treatment. Hepatic glutathione content (total) was measured and the data are presented as mean ± S.D. Hepatic glutathione content was significantly decreased 3, 6 and 9 hr after bromobenzene treatment, and recovered 24 hr after treatment, although the glutathione level showed a high variability at this time point. **, p<0.01 determined by two-sample t-test.
an inverse correlation with hepatic glutathione content. The present study had two advantages compared with the BSO study previously reported. First, the glutathione-depleting mechanism differs from phorone (a reactor to GSH thiol) and BSO (an inhibitor of gammaglutamylcysteine synthetase). Comparing the two glutathione-depleting mechanisms, the phorone-induced one is thought to be more similar to drug-induced glutathione depletion (as in the acetaminophen overdoseinduced one) where hepatic glutathione is depleted by elevated elimination, not by inhibition of glutathione synthesis. Second, the present study set multiple dose ranges and time points. The total number of rats tested in the phorone study was 36 (twelve 400 mg/kg phorone-treated rats were excluded from the gene selection procedure), whereas the previous BSO study used only 8 rats (Kiyosawa et al., 2004) . Thus, the GSH probe sets identified in the present study would give us more reliable information for evaluation of the potential risk of drug-induced glutathione depletion.
The GSH probe sets contained antioxidant/phase II drug-metabolizing enzymes, oxidative stress markers, transporters, metabolism-related genes, transcription factors and signal transduction-related genes, and others. GSH probe sets contain a modifier subunit of glutamate cysteine ligase gene, which encodes a key enzyme for glutathione synthesis (Moinova and Mulcahy, 1999) . In addition, a prototypical oxidative stress-responsive gene, heme oxygenase I, which is reported to be regulated by oxidative stress sensor Nrf2 (Nguyen et al., 2003) , was identified as GSH probe sets. Furthermore, several genes were found to be in common with previously reported gene sets identified from the BSO-induced glutathione depletion model rat, such as GTP cyclohydrolase I and HMG-CoA reductase (Kiyosawa et al., 2004) . On the other hand, a PCA was performed using GSH probe sets for GeneChip data of rat livers 3, 6, 9 and 24 hr after 300 mg/kg bromobenzene treatment, as well as those 24 hr after treatment with hepatotoxicants, which are the same as those shown in Fig. 4 . Each spot colored by chemical types represents individual samples. Gene expression profiles of rats treated with bromobenzene did not show an apparent shift away from corresponding controls 3 and 6 hr after treatment. Those 9 and 24 hr after treatment showed an apparent shift from the controls.
difference in the content of probe sets, compared with that identified from BSO-treated rats was observed, for instance, glutathione S-transferase genes or metallothionein genes, which were induced by BSO but not by phorone (Kiyosawa et al., 2004) . Although the strain and the age of the rats were not matched between the two studies (6 week old male Crj:CD(SD)IGS rats vs. 9 week old male F344Cu/Drj rats) the difference could be mainly due to the difference of the GSHdepleting mechanism between phorone and BSO.
To examine the toxicological significance of the GSH probe sets, we conducted PCA on GeneChip data obtained from rats treated with 13 prototypical hepatotoxicants (Fig. 4) . On the PCA map, rats treated with bromobenzene, coumarin, and acetaminophen showed apparent changes in hepatic gene expression profiles, and those treated with thioacetamide showed slight changes (Fig. 4) . Bromobenzene-treated rats showed the most notable change in gene expression. Bromobenzene was reported to be oxidized to a reactive metabolite in liver, depleting hepatic glutathione (Chakrabarti, 1991; Heijne et al., 2004) .
Courmarin-treated rats showed the second most affected gene expression profile in PCA. It was reported that a single coumarin treatment reduced the hepatic content of non-protein sulfhydryl groups (Lake et al., 1989) , and this is thought to reflect the decrease in glutathione content. Furthermore, coumarin was shown to decrease glutathione content in rat hepatocyte as well (Lake et al., 1989) . Reactive metabolites generated from coumarin oxidation in liver were thought to play a role in coumarin-induced glutathione depletion and hepatotoxicity (Lake, 1984; Lake et al., 1989) . Since no apparent hepatotoxicity was evident in both the histopathology and plasma biochemistry data (Table 2) , the PCA result would reflect the potential risk of courmarin-induced glutathione-depletion.
Acetaminophen and thioacetamide are known to deplete or reduce glutathione in liver when overdosed (Mesa et al., 1996) . In the present study, acetaminophen-or thioacetamide treated rat showed no dramatic change in the gene expression profile compared to bromobenzene. Considering the plasma chemistry data, rats treated with acetaminophen or thioacetamide did not show apparent hepatotoxicity within 24 hr after single dose, whereas those treated with bromobenzene apparently showed it, suggesting that glutathione depletion, expression profile of GSH probe sets, and toxicological phenotype are well correlated with each other.
We also investigated the time-course of glutathione content and gene expression profile in rat livers treated with bromobenzene, and this showed the most notable gene expression change of all of the examined hepatotoxicants (according to the PCA result). Bromobenzene rapidly depleted hepatic glutathione 3 hr after treatment, and the glutathione content was the lowest 9 hr after treatment (Fig. 5) . Hepatic glutathione content recovered from initial depletion until 24 hr after the bromobenzene treatment, and such recovery has been previously reported (Chakrabarti, 1991; Heijne et al., 2004) . On the other hand, gene expression changes had not been apparent 3 and 6 hr after the bromobenzene treatment, but appeared 9 and 24 hr after treatment. Although hepatic glutathione content was recovered at 24 hr after the bromobenzene treatment, a changed level in gene expression was most prominent at this time point. This result depicts a characteristic of the gene expression profile in that it does not reflect the status of hepatic glutathione content itself, but the nuclear activity to maintain glutathione homeostasis in the liver against bromobenzene-induced glutathione depletion. It should be noted, that although the hepatic glutathione content was recovered 24 hr after bromobenzene treatment, the potential risk of bromobenzene-induced glutathione depletion does exist. In general, hepatic glutathione depletion caused by chemical treatments occurs immediately, followed by rapid recovery by glutathione re-synthesis (Meister and Anderson, 1983) . Since the time point of sacrifice in ordinal toxicity studies is set to 24 hr after chemical treatment in many cases, measurement of glutathione content might overlook the risk of the glutathione-depleting potential of the tested chemicals, because 24 hr is enough time for the recovery of glutathione content after acute glutathione depletion. Instead, gene expression profiling is considered to be appropriate for evaluating the glutathione-depleting potential of chemicals, rather than measuring glutathione content, especially in later time points of chemical treatment. This characteristic of gene expression profiling, namely toxicogenomics analysis, would allow for safety assessment of chemicals in drug development.
In conclusion, a total of 161 probe sets of RAE 230A GeneChip, referred as GSH probe sets, were identified using phorone-treated rats for evaluation of drug-induced glutathione depletion. The significance of the identified GSH probe sets was evaluated using the TGP database, where prototypical glutathione depletors successfully showed characteristic changes in the signal levels of GSH probe sets. The time-course of glutathione content and the gene expression profile showed that gene expression profiling could detect the glutathione-depleting potential of chemicals in later time points, e.g., 24 hr after chemical treatment, where hepatic glutathione content had recovered from acute and transient depletion at earlier time points. Therefore, toxicogenomics analysis using identified GSH probe sets would be an invaluable methodology for assessing a drug's potential risk of glutathione depletion, possibly leading to hepatotoxicity.
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